In this episode of the orange pill podcast, we spotlight a groundbreaking clinical trial that could redefine how omega-3s are delivered to the brain and eyes. Aker BioMarine has partnered with KGK Science to launch the first-ever human clinical trial on Lysoveta, a next-gen omega-3 ingredient that uses lyso-phosphatidylcholine (LPC) to deliver EPA and DHA across the blood-brain and blood-retina barriers. Why does that matter? Because targeted delivery to the brain and eyes has long been the holy grail of omega-3 science.
We dive into the science behind MFSD2A, the transporter protein that makes this possible, and how Lysoveta could change the game for cognitive function, mood, and healthy aging. With 138 participants, an 18-month timeline, and NDI status already secured in the U.S., this study marks a major leap toward validating LPC-bound omega-3s as a new category in nutraceutical and pharmaceutical development.
KGK Science has been delivering top-notch clinical research trials and expert regulatory support for the nutraceutical, cannabis, hemp, and psychedelic industries for over 27 years, aiding companies in bringing their products to global markets with custom trials and claim substantiation strategies.
Monday - Saturday 7:00 AM - 3:00 PM
